Latest News and Press Releases

FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a pan-American (ex-USA) pharmaceutical company, announced today that Samira Sakhia, President and Chief...

MONTRÉAL, 12 mai 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente...

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an...

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable...

MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United...

MONTRÉAL, 08 mai 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa filiale...

Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception MONTREAL, May 07, 2026 ...

Augmentation des prévisions des produits des activités ordinaires à une fourchette de 510 millions de dollars à 525 millions de dollarsNiveau record trimestriel des produits des activités ordinaires,...